Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Site search
Search
Toggle navigation
Contact Us
Subscribe
Promote Your Event
e-Edition
Privacy Policy
Terms of Service
Local Weather
Home Delivery
Submission Forms
News
Local News
The Leader
Heartland News
Sports
Entertainment
Local Events
Multimedia
Photo Galleries
Videos
Obituaries
Classifieds
Real Estate
Property for Rent
Cars & Vehicles
Jobs
Items for Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place an ad
Legals
Best of 2022
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cns Pharmaceuticals Inc
(NQ:
CNSP
)
1.170
-0.050 (-4.10%)
Streaming Delayed Price
Updated: 3:49 PM EDT, Sep 22, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Cns Pharmaceuticals Inc
< Previous
1
2
3
4
5
6
7
8
Next >
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Maintains Focus on Advancing Clinical Development Program for Lead Drug Candidate, Berubicin
November 14, 2022
Via
Investor Brand Network
Research Finds New Therapy Path for Brain Cancer
November 10, 2022
Via
Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Maintains Strong Cash Position as It Continues Drug Development Program Pursuing Treatment for GBM
November 10, 2022
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Targeted ‘Finish Line Is Within Sight’ as It Pursues Potential GBM Treatment
November 07, 2022
Via
Investor Brand Network
New Brain Cancer Clinical Trial Platform Launched in Australia
November 07, 2022
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Doses First Patient in Global Berubicin Trial Evaluating GBM Treatment
November 02, 2022
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin Shows Superior Performance to Other Anthracyclines, Standards of Care for GBM
October 31, 2022
Via
Investor Brand Network
Researchers Discover New Way to Noninvasively Monitor Immune Cells Inside Tumors
October 27, 2022
Via
Investor Brand Network
Patient Plays Sax During Lengthy Surgery to Remove Brain Tumor
October 20, 2022
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Anticipating 2023 IND Application for Secondary Portfolio Candidate
October 17, 2022
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Executes on Several Clinical, Operational Advancements in Pursuit of GBM Treatment
October 14, 2022
Via
Investor Brand Network
Researchers Uncover Vital Clues on Drivers Behind Growth, Size of Brain Tumors
October 13, 2022
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO to Participate in Breakthrough for Brain Tumors(R) 5K Run
October 10, 2022
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Advancement of Berubicin Clinical Trial Featured in Syndicated Broadcast
October 07, 2022
Via
Investor Brand Network
New Laws on Abortion May Complicate Cancer Treatment for Pregnant Patients
October 06, 2022
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Poised to Bring ‘Potentially Impactful’ Therapy to GBM Patients
October 03, 2022
Via
Investor Brand Network
Exposures
Product Safety
UC San Diego Offers New Radiation Therapy That Prevents Tumor Regrowth
September 30, 2022
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Activates First European Sites for Potentially Pivotal Clinical Trial
September 28, 2022
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present at Virtual Investor Innovations in Oncology Event
September 23, 2022
Via
Investor Brand Network
Study Finds That Endometriosis Prognosis Worsens as CNS Metastasis Occurs
September 23, 2022
Via
Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Participates in H.C. Wainwright 24th Annual Global Investment Conference, Presenting Key Investor Highlights on Novel Anthracycline Berubicin for GBM Treatment
September 19, 2022
Via
Investor Brand Network
TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Leading Charge to Find Potential Treatment Option for GBM
September 16, 2022
Via
Investor Brand Network
Focused Ultrasound May Offer Easier Way to Treat Brain Tumors Effectively
September 15, 2022
Via
Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Takes Aim at Thus-far Incurable GBM Brain Cancer with Human Drug Trials
September 13, 2022
Via
Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Efforts to Combat GBM Brain Cancer Proceed Amid Competitive Field
September 09, 2022
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present at H.C. Wainwright 24th Annual Global Investment Conference
September 07, 2022
Via
Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Posts Slight Q2 2022 Performance Improvement; Maintains Priorities and Focus on Advancing its Clinical Development Program for Berubicin
September 07, 2022
Via
Investor Brand Network
Accessibility Issues Prevent Individuals in Rural Areas from Undergoing Lifesaving Tumor Treatment
September 07, 2022
Via
Investor Brand Network
Topics
Death
Exposures
Death
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP), Moving the Needle in GBM and Brain Cancer Research
September 01, 2022
Via
Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Looking to Fill Glioblastoma Multiforme Treatment Gap with Berubicin Drug Product
August 30, 2022
Via
Investor Brand Network
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.